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Gentamicin pharmacokinetics during hemodialysis. Previous
research has permitted the development of a method for the
estimation of gentamicin dosage requirement for varying
degrees of renal insufficiency. In the present study we have under-
taken precise measurement of the Kiil hemodialyzer clearance
of gentamicin and have extended earlier kinetic models to
facilitate gentamicin administration to dialysis patients. Due to
the dialysis characteristics of gentamicin, the results can be
extrapolated to gentamicin administration when other hemo-
dialyzers are employed. Our findings also demonstrate the
significance of residual renat function in dialysis patients in the
determination of gentamicin dosage requirements.
Pharmacocinétique de Ia gentamycinc an cours de l'hémodialyse.
Des travaux antérieurs ont permis le développement d'une
méthode d'estimation de la posologie de gentamycine nécessaire
a différents degrés d'unsuffisance rénale. Ce travail comparte des
mesures précises de la clearance de la gentamycine dans l'hbmo-
dialyseur de Kiil eta développé des modeles cinétiques antérieurs
afin de faciliter l'administration de gentamycine aux malades
soumis 6 l'hémodialyse. Du fait des caractéristiques de dialyse
de la gentamycine les résultats peuvent étrc extrapolés 6 l'admini-
stration de gentamycine même quand d'autres modéles d'hémo-
dialyseurs sont employés. Cette étude démontre nussi l'impor-
tance d'une fonction rénale résiduelle dans Ia determination de
la posologie de la gentamycine pour les malades soumis 6
l'hémodialyse.
Gentamicin is an aminoglycoside antibiotic derived
from Micromonaspora purpurea and is rapidly bac-
tericidal for a wide variety of common pathogens
[1, 2]. Clinically, however, it is mainly used in gram
negative infections, especially with pseudomonas,
proteus, klebsiella and enterobacter.
Previous studies have shown that gentamicin is not
metabolized to a significant extent and is eliminated
from the body principally by renal excretion [3—5]. As
gentamicin is potentially ototoxic when plasma concen-
trations exceed 12 mg/liter and excretion is impaired
[6—7], dosage should be reduced with decreased renal
function to maintain drug concentrations in the range
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of 2 to 10 mg/liter depending on the bacterial sensiti-
vity. Although nephrotoxicity is also possible, the
incidence has been very low and usually is associated
with other causes of renal insufficiency [8—10].
Gentamicin is a basic compound consisting of a
mixture of closely related molecules with a molecular
weight range of 425 to 476. Its apparent distribution
volume has been reported to be 24% of the body wt
[3], and plasma protein binding has been reported to
be negligible [4, 11].
Several studies have been done in order to provide
information about adjustment of dosage of genta-
micin for neonates and for patients with impaired
renal function [3—5, 12—15]. Little information, how-
ever, is available in the literature about gentamicin
pharmacokinetics in patients with end-stage renal
failure and receiving intermittent hemodialysis [4, 16,
17].
Our study was undertaken to verify the pharma-
cokinetic properties of gentamicin in patients with end-
stage renal failure on intermittent hemodialysis in order
to determine its volume of distribution and dialyzer
clearance, and what dosage adjustment should be
made in these particular situations.
Methods
The series consisted of 11 patients, all of them with
end-stage renal failure and on a regular dialysis
schedule of eight hours, three times a week. All of
them had arteriovenous (A-V) cannulas placed in the
forearm and were in a stable condition. Patients taking
part in pharmacokinetic studies had not received
gentamicin or other ototoxic antibiotics for at least
three weeks prior to the study. In the chronic admini-
stration studies, the patients were receiving genta-
micin for therapeutic purposes.
Six men and five women, whose ages ranged from 22
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to 60 yr, participated. After a written consent was
obtained, two series of experiments were performed at
the Clinical Research Center:
1. Dialysate loop experiment. A diagram of this
experiment is represented in Fig. 1. Prior to a regular
dialysis using a standard Ku! Dialyzer with Cupro-
phan membrane, the patient was dialyzed for 90 mm
against a 1000-ml volume closed dialysate loop with a
countercurrent recirculation rate of 500 ml/min. In
every experiment, a blood pump was used and was
adjusted to provide a blood flow of 200 ml/min.
Gentamicin sulfate (50 mg of gentamicin base diluted
in 30 ml of 0.9% sodium chloride solution) was injec-
ted into the dialysate loop from a weighed syringe. An
aliquot of the injected solution was assayed for genta-
micin and the volume of the solution injected was
estimated from a postinjection syringe weight. Dialy-
sate samples were collected at 5-mm intervals for 90
mm and blood samples were collected from the
arterial line at 1 5-mm intervals. In order to minimize
ultrafiltration, a pressure gauge was placed at the
inflow to the dialyzer in the dialysate loop circuit to
assure that the transmembrane ultrafiltration pressure
was low and, in fact, no "negative pressure" was
applied to the hemodialyzer. During the experiment,
the dialysate reservoir volume was monitored for
stability and at the end of the 90 mm, the final volume
of the dialysate was measured. At the termination of
the loop experiment, the patient was given a standard
dialysis. Blood samples were assayed for creatinine
concentration using the autoanalyzer method based
on the Jaffe reaction [18]; gentamicin concentrations
were measured by the method of Smith, Van Otto and
Smith [19].
2. Studies between dialysis. The same subjects who
participated in the dialysis loop experiment were
studied after an interval of 14 to 21 days. They were
admitted to the Clinical Research Center shortly after
the termination of a regular dialysis. Gentamicin
sulfate (2 mg/kg of body wt of gentamicin base diluted
in 30 ml of 0.9% sodium chloride solution) was
injected intravenously from a weighed syringe. An
aliquot of the solution was assayed for gentamicin and
the volume of the injected solution was estimated from
a postinjection syringe weight. Serial blood samples
were collected at 1 5-mm intervals for two hours and
subsequently at less frequent intervals over a period of
24 to 30 hr, or until the patient's next dialysis. All
voided urine was collected and assayed for gentamicin.
Renal clearance for gentamicin and creatinine was
measured from 24-hr urine collections and the mean
plasma concentrations.
3. Long-term studies. These were undertaken in five
subjects who required gentamicin for therapeutic
purposes. Dosages of gentamicin were based on the
recommendations which were derived from the current
experiments. The length of dialysis and dialysis sched-
ules of these patients were determined by the North-
west Kidney Center and not adjusted for this study.
Some of the patients were hospitalized but, for the
majority of the dialyses, the patients returned home
and postinjection samples were not available for
analysis. Thus, these studies were a reasonable simula-
tion of clinical practice.
4. Plasma protein-binding studies. Protein-binding
studies were undertaken using two methods—the
column technique of Hummel and Dreyer [20] and
ultrafiltration. Findings confirmed that no plasma
protein binding was occurring, as reported by Gordon,
Regamey and Kirby [11], and previously by us [4].
Analysis of data. The in vitro dialyzer loop studies
were analyzed by means of a closed, well-mixed two-
pool model. The solutions of the equations for this
model are well-known and, in the absence of protein
binding and renal and nonrenal clearance, the con-
centration difference changes can be described by a
simple relationship:
f(V1+V2)= C0exp— , Kt
I_ Vj V2
where C =concentration difference between com-
partments; LC0 =concentration difference at t =0;
V2 =dialysate loop volume; V1 =volume of genta-
micin distribution in the patient; K=dialysance of
the dialyzer, which is numerically equal to the dialyzer
clearance in single pass operations; and t = time after
injection.
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Fig. 1. Diagram of dialysate loop experiment.
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This equation assumes that ultrafiltration does not
occur. In our experiments, the gentamicin concentra-
tions in both the blood and dialysate compartments
were measured and the dialysate volume was held
constant.
Now if we let V1/V2 =3, we can rewrite equation 1 so
that
rll+3\ 1n 1AC = AC0 exp— Ra_).v_.tj.
We see that (1 + 3)/3—*l as 8—>t.
In our patients, the dialysate loop volume was one
liter and the distribution volume for gentamicin in
the dialysis patients was equal to 24% of the body wt.
Thus, in our studies, V1/V2  10 and (1 + 3)18  11/10.
Therefore, in these studies the equation approaches:
AC = AC0 exp— I!i ti'
where V2 =dialysate volume and is constant. This
technique was used to measure both creatinine and
gentamicin clearances.
Analysis of experiments undertaken between dialyses.
In the experiments which were undertaken between
dialyses, the excretion of gentamicin was studied by
means of a single compartment model. Thus, the rapid
initial equilibration data collected in the first hour
were analyzed separately. For the subsequent data, the
natural logarithm of the date measured as a function of
time was fitted by a least squares routine COLNRS
available in the General Electric time-sharing pro-
grams. The standard deviation of the measured slope
permitted estimation of the difference of the slope from
zero. The intercept of the slope at zero time permitted
estimation of the volumes of distribution of the drug.
Renal clearance was estimated from the urine collec-
tions and the mean plasma gentamicin concentration.
Results
The experiments revealed that the in vivo mean
gentamicin clearance for the Kiil dialyzer was 24
ml/min (Table I). The creatinine clearance measured
simultaneously was 77 ml/min. Studies undertaken
when the patients were not on dialysis revealed that
the mean plasma gentamicin clearance was 4.7 ml/min
and the mean renal gentamicin clearance was 1.6 ml/
mm. It should be noted that these data include some
subjects who were functionally anephric. When
anephric subjects were excluded, the mean plasma
clearance was 6.1 ml/min and the mean renal clear-
ance was 3.2 mI/mm. Studies of the functionally and
surgically anephric subjects showed that the plasma
gentamicin decay curves were significantly different
Index Subjects,
N
Volume of distribution 9 24% of body wt 4.0
Residual plasma clearance 9 4.7 ml/min± 2.26
Renal clearance 9 1.6 mI/mm 1.46
Plasma clearance (anephric) 2 2.2 mI/mm
Dialyzer clearance 5
Creatinine 77 ml/min± 22
Gentamicin 24 mI/mm 0.6
from zero (P.c 0.05). The mean plasma gentamicin
clearance for these studies was 2.2 mI/mm.
The kinetics of gentamicin equilibration in the body
following i.v. injection was studied and demonstrated
that equilibration approximated a two-compartment
closed model with a mean tf for equilibration of 28
mm, with individual values ranging between 9 and 43
mm. Thus, for the first 30 to 60 mm following an i.v.
injection of gentamicin, considerable redistribution of
the drug may be occurring (Fig. 2). However, for
practical purposes, the drug excretion in functionally
anephric patients may be simulated by a one-compart-
ment model, and the transiently higher concentrations
illustrated in Fig. 2 persist for less than 2% of the total
duration of drug action. Thus, the volume of distri-
bution was computed from the intercept of the mono-
exponential portion of the decay curve, with the results
shown in Table 1. Previous studies of the excretion
kinetics of gentamicin in patients with varying degrees
of renal insufficiency and not on dialysis have shown
the drug to be predominantly excreted by the kidney.
Table 1. Physiologic data for gentamicin
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Fig. 2. Initial equilibration of gentaniicin in an anephric dialysis
patient following i.v. injection.
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The absence of plasma protein-binding again shown
in this study, and the high correlation between genta-
micin renal clearance and measured glomerular
filtration rate (GFR) [2, 3], suggests that the principal
mechanism of elimination of this drug is glomerular
filtration. Furthermore, the finding that the volume of
distribution for gentamicin is similar to the extra-
cellular volume measured by small molecules in nor-
mal subjects suggests that gentamicin is able to pene-
trate this space. However, the extent to which it
penetrates the intracellular compartment must be
minimal. Individual tissues such as the middle ear or
liver may show varying permeability to the drug, but
in quantitative terms of elimination and replacement,
this effect may be neglected. The discrimination be-
tween a nonrenal plasma clearance and slow tissue-
binding requires either the demonstration that these
binding sites eventually saturate, or the demonstration
of progressive gentamicin accumulation in a tissue. In
quantitative terms, if tissue-binding sites were to re-
move gentamicin from the plasma with a clearance of
2 to 3 ml/min, approximately one-fourth of each dose
would be removed via this route daily.
The therapeutic trials which were given were de-
signed to test for drug accumulation. The results
suggest either that such accumulation is not occurring
or that over the usual period of gentamicin therapy of
one to three weeks, significant accumulation of the drug
cannot be demonstrated.
Various techniques have been suggested for com-
puting the plasma gentamicin t4 in patients with renal
insufficiency. The most simple is probably that of
McHenry et al [12] and Cutler et al [4], who have
shown that the gentamicin tf (in hours) is equal to
three to four times the serum creatinine concentration
(in mg/lOO ml). There have been few studies to investi-
gate gentamicin administration in patients on dialysis.
In patients using dialysis, the amount of gentamicin
removed by the residual renal function and the
intermittent artificial kidney treatment, together with
the amount of drug removed by any nonrenal routes,
must be considered in the treatment regimen.
In the studies which have been outlined, we have
shown that the single injection measurement of
gentamicin distribution volume compared very well
with previous estimates in normal subjects. The study
also demonstrates (Fig. 3) that residual renal function
plays an important role in determining dosage require-
ments. If the interdialysis interval in an average subject
is approximately 48 hr and the residual renal genta-
micin clearance is 5.0 ml/min, an injection of genta-
micin given immediately following a dialysis will
produce a plasma gentamicin concentration at the
commencement of the next dialysis about one-half
that of the early postinjection value. In our studies
with functionally anephric subjects, we noted that the
mean plasma clearance was 2.2 ml/min and that it
differed significantly from zero. However, the 95%
confidence interval was sufficiently close to zero that
we feel it necessary for clinical purposes to make the
initial assumption that surgically anephric subjects will
have no clinically significant gentamicin elimination.
Thus, the difference between the measured plasma
gentamicin clearance and the measured renal clearance
could well represent the difficulties in urine collection
in oliguric subjects rather than being due to extra-
renal clearance of gentamicin. However, it is inter-
esting to note that gentamicin is recoverable from the
bile [31]. Although the hepatic clearance has not been
measured, this route of excretion may account for the
decay curve seen in the functionally or surgically
anephric patients previously mentioned. As this route
of elimination is in general extremely small and has
not been quantitated, we feel that for practical thera-
peutic purposes it would be advisable to assume that
no significant hepatic gentamicin clearance is taking
place. This assumption provides a margin of safety in
the administration of gentamicin and at the same time
avoids the potential risk of overdosage in patients who
may lack a significant hepatic route of elimination.
Furthermore, serial measurement of blood gentamicin
concentration would permit slightly increased dosages
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Fig. 3. Demonstration of the effect of a residual gentamicin
plasma clearance on concentrations before and after dialysis.
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in those patients in whom significant hepatic genta-
micin excretion may occur.
The dialysate loop studies which we have outlined
were employed to better measure gentamicin clearance
by the dialyzer because the slow removal rate of
gentamicin by the artificial kidney makes clearance
measurements by the A-V difference technique of
measuring dialyzer clearance technically difficult [22].
There was a remarkable uniformity of the results,
which might be expected if the rates of gentamicin
clearance were predominantly limited by the area and
permeability of the dialyzer membranes and were
relatively independent of the blood and dialysate
flow rates. In order to investigate this effect in more
detail, we have computed h0A (the mass transfer
coefficient x dialyzer membrane area) for gentamicin
in these experiments. This term is defined in equations
given by Babb et al [23]. The value of h0A defines for a
given dialyzer the maximum clearance in single pass
dialysis which can be achieved for a particular mole-
cule with laminar flow conditions and with negligible
ultrafiltration rate. Based on the equations relating
dialyzer clearance to h0A, the h0A value for genta-
micin in a Kiil dialyzer is 26 mI/mm.
The h0A value that we obtained suggests that
gentamicin behaves as a poorly dialyzable molecule
with clearance relatively independent of blood and
dialysate flow rate and markedly dependent on dialy-
zer membrane surface area and its permeability
characteristics. Thus, dialyzers with similar effective
surface areas employing membranes with similar
permeability characteristics to Cuprophan should
behave in a similar manner. We would expect that coil
dialyzers and Dow and Gambro units would exhibit
approximately similar clearance values and our
preliminary studies in these dialyzers confirm this
conclusion. Using the results obtained, the predicted
plasma concentrations which would be expected from
a therapeutic regimen in which gentamicin is admini-
stered i.v. or i.m. three times a week (after each hemo-
dialysis) to patients with negligible plasma clearance
and in those with minimal residual renal function is
shown in Fig. 3. We, therefore, recommend that in
anephric subjects the gentamicin dose should be 50%
of the loading dose following each dialysis; in subjects
with residual creatinine clearance of 5 ml/min, the
gentamicin dosage should be 75% of the loading dose
after each dialysis. Fig. 4 gives more specific predictions
for patients with varying body weights.
Our therapeutic predictions correlate quite well with
those of Gingell and Waterworth [5], who recom-
mended the administration of 80 mg of gentamicin
after each dialysis. However, their studies did not
directly measure gentamicin clearance by the dialyzer
and were based on twice-weekly dialysis. In contrast to
these results, however, Riff and Jackson [16], using an
EXO3 coil dialyzer, found that the gentamicin clear-
ance was as high as 607 of the creatinine clearance.
However, recent studies in our laboratory have not
confirmed this report. Recent reports [24—26] reveal
considerable differences in clearance measurement and
emphasize the problems of these types of studies. The
A-V difference technique in which the relative error of
an A-V measurement can be as high as 5070 with
enzymatic or microbiologic assay is particularly hazard-
ous. The use of plasma concentration decay curves
during dialysis, while permitting measurement of the
total plasma clearance, does not directly measure the
dialyzer clearance. In our studies we have found it
necessary to assay more than 20 samples per study in
order to define a decay curve with sufficient precision
to be able to make satisfactory gentamicin clearance
measurements.
In order to substantiate our predictions, we have
studied serial predialysis and postdialysis gentamicin
concentrations in five dialysis patients receiving
gentamicin therapeutically using the dosage regimens
that we have outlined herein. The results are shown in
Table 2. From the calculated distribution volume, it
can be seen that 1.5 mg/kg of body wt of gentamicin
(base) would raise the plasma concentration by a mean
value of 6 mg/liter. The postdialysis concentrations of
gentamicin were sufficiently low that elevation of the
plasma concentration by 6 mg/liter should not bring
the drug concentrations into the toxic range. Patient 1
represents an unusual pattern as he had been surgi-
cally nephrectomized. This patient was studied for
three weeks and had customary dialysis with a Kiil. It
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Table 2. Data from dialysis patients being maintained on
gentamicin therapy
Patient Loading Sustaining Gentamicin Samples
No. dose dose concentrations N
Before After
dialysis dialysis
1 2mg/kg 1mg/kg 1.3± 1.9 0.6±0.3 7
2 2 mg/kg 1 mg/kg 4.6± 1.3 2.6±0.7 7
3 2mg/kg 1 mg/kg 5.5± 1.0 2.4± 0.4 7
4 2mg/kg 1.3mg/kg 4.0±1.3 2.8±1.0 13
5 2 mg/kg 1 mg/kg 4.9 2.2 3.28 1.6 9
seems unlikely that this patient was accumulating
drug in a large unidentified pool, and we suggest that
he had a markedly increased nonrenal clearance.
Further details on this patient will be reported else-
where.
It is interesting to note that Curtis, McDonald and
Weston [17] detected unusually high peak gentamicin
concentrations in two dialysis patients following i.v.
administration. These concentrations were measured
only 10 mm after the injection and when compared to
the equilibration t+, illustrated in Fig. 2, might be
expected to fall toward the normal therapeutic values
within 60 to 120 mm. The dialysis results which they
published showed that the postdialysis concentrations
of gentamicin were usually 2 mg/liter or less, and thus
are comparable with the postdialysis concentrations
predicted from Fig. 3. It should be noted that their
management regimen involved Kiil dialysis admini-
stered twice weekly for a total of 28 hr.
In conclusion, we emphasize that the results and
predictions of this study are intended only as guide-
lines for drug administration for patients based on
thrice-weekly dialysis schedules totalling 18 to 24 hr/
week with a hemodialyzer having clearance rates
similar to those of a Kiil.
We would recommend that, following the first
loading of gentamicin, a one-hour postinjection blood
level together with predialysis and postdialysis con-
centrations of the next succeeding dialysis should be
measured. Subsequently, the use of blood samples
drawn one hour following gentamicin injection or the
measurement of blood concentrations immediately
before dialysis will permit modifications of the dosage
regimens. Following changes in the dosage of genta-
micin, the equilibration to a new therapeutic level
might be expected to occur over a one-week period;
care must therefore be taken to observe serum concen-
tration of the drug for delayed effects when dosage
changes are made. It should also be noted that with
increased frequency of dialysis, interdialysis dosages
may need to be slightly lowered. For example, patients
on daily dialysis of eight hours might be expected to
need approximately 50% of the loading dose after each
dialysis.
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